Literature DB >> 32194887

The emerging role of circulating tumor cells in cancer management.

Xue-Yao Li1, Man Dong2, Xiang-Yang Zang1, Miao-Ya Li1, Jing-Yi Zhou1, Jian-Jun Ma1, Gang-Yang Wang3.   

Abstract

Circulating tumor cells (CTCs) are cells that are shed from the primary tumor and circulate in the blood, and their metastasis and formation of a secondary tumor are closely associated with cancer-related death. Therefore, regulating tumor metastasis through CTCs can be a novel strategy to fight cancer. It has been demonstrated that CTCs can reflect the profile of the primary tumor and provide valuable information about intratumoral heterogeneity and their evolution over time. Moreover, the revelation of the relationship between metastasis and CTCs suggests that CTC regulation represents a promising novel anticancer strategy. Above all, at the molecular level, genetic analysis might be vital in the new era of gene-targeted cancer therapies and contribute to personalized anti-metastasis tumor treatments. In this review, we will focus on the biological significance of CTCs in the peripheral blood and discuss their potential clinical implications in cancer management. AJTR
Copyright © 2020.

Entities:  

Keywords:  Circulating tumor cells; cancer metastasis; clinical significance; enrichment technology; epithelial-mesenchymal transition; molecular analysis

Year:  2020        PMID: 32194887      PMCID: PMC7061830     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  81 in total

1.  Cancer cells in the circulating blood; a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation.

Authors:  H C ENGELL
Journal:  Acta Chir Scand Suppl       Date:  1955

2.  Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.

Authors:  Yanyan Lou; Lixia Diao; Edwin Roger Parra Cuentas; Warren L Denning; Limo Chen; You Hong Fan; Lauren A Byers; Jing Wang; Vassiliki A Papadimitrakopoulou; Carmen Behrens; Jaime Canales Rodriguez; Patrick Hwu; Ignacio I Wistuba; John V Heymach; Don L Gibbons
Journal:  Clin Cancer Res       Date:  2016-02-05       Impact factor: 12.531

Review 3.  Premetastatic niche: ready for new therapeutic interventions?

Authors:  Alice Zoccoli; Michele Iuliani; Francesco Pantano; Marco Imperatori; Salvatore Intagliata; Bruno Vincenzi; Paolo Marchetti; Nicola Papapietro; Vincenzo Denaro; Giuseppe Tonini; Daniele Santini
Journal:  Expert Opin Ther Targets       Date:  2012-03-23       Impact factor: 6.902

4.  Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.

Authors:  Matthew G Krebs; Jian-Mei Hou; Robert Sloane; Lee Lancashire; Lynsey Priest; Daisuke Nonaka; Tim H Ward; Alison Backen; Glen Clack; Andrew Hughes; Malcolm Ranson; Fiona H Blackhall; Caroline Dive
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

5.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

Review 6.  The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells.

Authors:  Huiying Liu; Xiaofeng Zhang; Jun Li; Bin Sun; Haihua Qian; Zhengfeng Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

7.  Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis.

Authors:  Long Cui; Joseph Kwong; Chi Chiu Wang
Journal:  J Ovarian Res       Date:  2015-06-16       Impact factor: 4.234

8.  A microfluidic device for label-free, physical capture of circulating tumor cell clusters.

Authors:  A Fatih Sarioglu; Nicola Aceto; Nikola Kojic; Maria C Donaldson; Mahnaz Zeinali; Bashar Hamza; Amanda Engstrom; Huili Zhu; Tilak K Sundaresan; David T Miyamoto; Xi Luo; Aditya Bardia; Ben S Wittner; Sridhar Ramaswamy; Toshi Shioda; David T Ting; Shannon L Stott; Ravi Kapur; Shyamala Maheswaran; Daniel A Haber; Mehmet Toner
Journal:  Nat Methods       Date:  2015-05-18       Impact factor: 28.547

9.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

10.  Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.

Authors:  Nicola Aceto; Aditya Bardia; David T Miyamoto; Maria C Donaldson; Ben S Wittner; Joel A Spencer; Min Yu; Adam Pely; Amanda Engstrom; Huili Zhu; Brian W Brannigan; Ravi Kapur; Shannon L Stott; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Charles P Lin; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran
Journal:  Cell       Date:  2014-08-28       Impact factor: 41.582

View more
  1 in total

1.  Single-Cell Analysis of BRAFV600E and NRASQ61R Mutation Status in Melanoma Cell Lines as Method Generation for Circulating Melanoma Cells.

Authors:  Joseph W Po; Yafeng Ma; Alison W S Luk; David Lynch; Bavanthi Balakrishnar; Daniel Brungs; Farhad Azimi; Adam Cooper; Erin Saricilar; Vinay Murthy; Paul de Souza; Therese M Becker
Journal:  Methods Mol Biol       Date:  2021
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.